Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides an update on the AMEERA-3 (NCT04059484), ongoing Phase II study of SAR439859, an oral selective estrogen receptor degrader (SERD), versus endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer with prior exposure to hormonal therapies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
